GSK looks to authorized generic version of asthma treatment as Medicaid rebate caps lift next year
GSK is gearing up to discontinue the brand-name version of its asthma medication Flovent, just as the Medicaid rebate cap is ending in January 2024, pushing some manufacturers to change up what they’re doing to avoid steep rebates.
GSK notified the FDA earlier this year that it would discontinue the company’s brands Flovent HFA and Flovent Diskus, popular treatments for asthma. The company will instead offer authorized generic versions of the products moving forward. Authorized generics are considered by the FDA to be exact copies of the brand-name versions, and they typically come with a lower price tag.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
